Shanda Blackmon/sts.org
Jun 1, 2025, 16:46
Shanda Blackmon: First trial of CAR-T cell cancer treatment for solid tumor response
Shanda Blackmon, Professor Of Surgery in the Division of Thoracic Surgery at Baylor College of Medicine and Director of the Lung Institute at Baylor Medicine, shared on X:
“First trial of CAR-T cell cancer treatment for solid tumor response:
Satricabtagene autoleucel (satri-cel)/CT041 demonstrated significant progression-free survival (PFS) improvement and a clinically meaningful overall survival (OS) benefit in patients with previously treated, advanced G/GEJC.
Globally, this is the first ever randomized controlled trial of a CAR-T cell therapy in
solid tumors to achieve superiority.Satri-cel showed a manageable safety profile consistent with previous phase I results. This trial expanded the percentage of CLDN18.2 positive patients with G/GEJC.
These results support satri-cel as a new treatment option for advanced G/GEJC.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40